Dataset Information


A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG.

ABSTRACT: BACKGROUND:The aim of the study is to demonstrate that intrapatient dose escalation of carboplatin would improve the outcome in ovarian cancer compared with flat dosing. PATIENTS AND METHODS:Patients with untreated stage IC-IV ovarian cancer received six cycles of carboplatin area under the curve 6 (AUC 6) 3 weekly either with no dose modification except for toxicity (Arm A) or with dose escalations in cycles 2-6 based on nadir neutrophil and platelet counts (Arm B). The primary end-point was progression-free survival (PFS). RESULTS:Nine hundred and sixty-four patients were recruited from 71 centers. Dose escalation was achieved in 77% of patients who had ?1 cycle. The median AUCs (cycle 2-6) received were 6.0 (Arm A) and 7.2 (Arm B) (P < 0.001). Grade 3/4 non-hematological toxicity was higher in Arm B (31% versus 22% P = 0.001). The median PFS was 12.1 months in Arm A and B [hazard ratio (HR) 0.99; 95% confidence interval (CI) 0.85-1.15; P = 0.93]. The median overall survival (OS) was 34.1 and 30.7 months in Arms A and B, respectively (HR 0.98; 95% CI 0.81-1.18, P = 0.82). In multivariate analysis, baseline neutrophil (P < 0.001), baseline platelet counts (P < 0.001) and the difference between white blood cell (WBC) and neutrophil count (P = 0.009) had a significant adverse prognostic value. CONCLUSIONS:Intrapatient dose escalation of carboplatin based on nadir blood counts is feasible and safe. However, it provided no improvement in PFS or OS compared with flat dosing. Baseline neutrophils over-ride nadir counts in prognostic significance. These data may have wider implications particularly in respect of the management of chemotherapy-induced neutropenia.

SUBMITTER: Banerjee S 

PROVIDER: S-EPMC4669851 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6510847 | BioStudies
2020-01-01 | S-EPMC7028795 | BioStudies
2011-01-01 | S-EPMC3185947 | BioStudies
2016-01-01 | S-EPMC4915081 | BioStudies
2014-01-01 | S-EPMC4260026 | BioStudies
1000-01-01 | S-EPMC5719445 | BioStudies
2018-01-01 | S-EPMC6853187 | BioStudies
1000-01-01 | S-EPMC3968310 | BioStudies
2019-01-01 | S-EPMC6544459 | BioStudies
2020-01-01 | S-EPMC6918895 | BioStudies